GeNeuro, Servier deal

GeNeuro granted Servier an option to license exclusive rights to develop and commercialize GNbAC1 worldwide, excluding the U.S. and Japan. Servier will pay GeNeuro $47 million up front for the option and can exercise the option after GeNeuro completes a Phase IIb trial of GNbAC1 to treat multiple sclerosis. If Servier exercises the option, it will pay for worldwide Phase III development costs of GNbAC1 and GeNeuro would be eligible for $408 million in milestones, plus royalties. Servier also has an option to take an undisclosed minority equity stake in GeNeuro within 12 months. ...